AbbVie (WBO:ABBV) Total Tax Payable : €0 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is AbbVie Total Tax Payable?

AbbVie's Total Tax Payable for the quarter that ended in Mar. 2024 was €0 Mil.

AbbVie Total Tax Payable Historical Data

The historical data trend for AbbVie's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Total Tax Payable Chart

AbbVie Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Tax Payable

Get a 7-Day Free Trial

AbbVie Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Tax Payable	Get a 7-Day Free Trial															-	-	-	-	-

AbbVie Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

AbbVie Total Tax Payable Related Terms

Thank you for viewing the detailed overview of AbbVie's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

AbbVie (WBO:ABBV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (WBO:ABBV) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

ABBV:USA ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB:Germany ABBV:Canada ABBV34:Brazil

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.